Kewaunee Scientific Sales Soar Post-Acquisition, But Profitability Mixed

Ticker: KEQU · Form: 10-Q · Filed: Dec 12, 2025 · CIK: 55529

Sentiment: mixed

Topics: Acquisition, Revenue Growth, Net Earnings, Operating Expenses, Interest Expense, Laboratory Equipment, Financial Performance

Related Tickers: KEQU

TL;DR

**KEQU's Nu Aire acquisition is driving massive sales growth, but watch those rising expenses and interest costs eating into quarterly profits.**

AI Summary

KEWAUNEE SCIENTIFIC CORP /DE/ reported a significant increase in net sales for the three months ended October 31, 2025, reaching $70.096 million, up from $47.764 million in the prior year, a 46.7% increase. For the six months, net sales grew to $141.200 million from $96.157 million, a 46.8% increase. Despite this revenue growth, net earnings attributable to Kewaunee Scientific Corporation stockholders decreased by 18.7% to $2.445 million for the three-month period, down from $3.008 million. However, for the six-month period, net earnings increased by 6.5% to $5.538 million from $5.201 million. The acquisition of Nu Aire, Inc. on November 1, 2024, for $53.0 million significantly contributed to the revenue growth, adding $19.4 million in revenue for the three months and $39.1 million for the six months ended October 31, 2025. Operating expenses rose substantially to $15.613 million for the three months, up from $9.518 million, and interest expense more than doubled to $1.061 million from $0.442 million, impacting profitability. The company's cash and cash equivalents decreased from $14.942 million on April 30, 2025, to $12.594 million on October 31, 2025, reflecting increased capital expenditures of $2.341 million and net cash used in financing activities of $2.316 million.

Why It Matters

This filing reveals KEQU's aggressive growth strategy through the Nu Aire acquisition, which has significantly boosted revenue but also increased operating and interest expenses. For investors, the mixed earnings picture—a quarterly dip despite strong sales, but a six-month gain—suggests integration challenges or higher operational costs post-acquisition. Employees of both KEQU and Nu Aire will see the combined entity aiming for market leadership in laboratory furnishings, potentially leading to new opportunities or restructuring. Customers could benefit from an expanded product portfolio and enhanced capabilities. In the broader market, this acquisition intensifies competition in the specialized laboratory equipment sector, potentially prompting other players to consolidate or innovate.

Risk Assessment

Risk Level: medium — The company faces medium risk due to increased interest expense, which more than doubled to $1.061 million for the three months ended October 31, 2025, from $0.442 million in the prior year, indicating higher debt servicing costs. Additionally, operating expenses increased significantly to $15.613 million from $9.518 million, suggesting potential integration costs or higher overhead post-acquisition, which could pressure future margins.

Analyst Insight

Investors should closely monitor KEQU's next few quarters for signs of successful integration of Nu Aire and cost control. While revenue growth is strong, the decline in quarterly net earnings and rising expenses warrant caution. Consider if the long-term strategic benefits of the acquisition will outweigh the short-term financial pressures.

Financial Highlights

debt To Equity
N/A
revenue
$70.096M
operating Margin
5.86%
total Assets
N/A
total Debt
N/A
net Income
$2.445M
eps
$0.82
gross Margin
28.13%
cash Position
$12.594M
revenue Growth
+46.7%

Revenue Breakdown

SegmentRevenueGrowth
Nu Aire Acquisition$19.4MN/A

Key Numbers

Key Players & Entities

FAQ

How did KEWAUNEE SCIENTIFIC CORP's net sales perform in the latest quarter?

KEWAUNEE SCIENTIFIC CORP's net sales for the three months ended October 31, 2025, increased significantly to $70.096 million, up from $47.764 million in the same period last year, representing a 46.7% increase.

What was the impact of the Nu Aire acquisition on KEQU's financial results?

The acquisition of Nu Aire, Inc. on November 1, 2024, contributed $19.4 million in revenue and $1.1 million in net earnings for the three months ended October 31, 2025, significantly boosting KEQU's top-line growth.

Did KEWAUNEE SCIENTIFIC CORP's net earnings increase or decrease?

Net earnings attributable to Kewaunee Scientific Corporation stockholders decreased by 18.7% to $2.445 million for the three months ended October 31, 2025, compared to $3.008 million in the prior year. However, for the six-month period, net earnings increased by 6.5% to $5.538 million.

What are the key risks highlighted in KEQU's 10-Q filing?

Key risks include a substantial increase in interest expense, which more than doubled to $1.061 million for the three months, and a significant rise in operating expenses to $15.613 million, indicating potential pressures on profitability and higher debt servicing costs.

What is the strategic outlook for KEWAUNEE SCIENTIFIC CORP after the Nu Aire acquisition?

The Nu Aire acquisition expands KEWAUNEE SCIENTIFIC CORP's capabilities and accelerates its vision of becoming a market leader in laboratory furniture and technical products, aiming to better meet end-user needs in laboratory furnishings.

How did KEQU's cash position change during the period?

KEQU's cash and cash equivalents decreased from $14.942 million on April 30, 2025, to $12.594 million on October 31, 2025, primarily due to increased capital expenditures of $2.341 million and net cash used in financing activities of $2.316 million.

What were KEWAUNEE SCIENTIFIC CORP's operating expenses for the quarter?

Operating expenses for KEWAUNEE SCIENTIFIC CORP were $15.613 million for the three months ended October 31, 2025, a notable increase from $9.518 million in the same period of the previous year.

What should investors consider regarding KEQU's performance?

Investors should consider the strong revenue growth driven by the Nu Aire acquisition against the backdrop of increased operating and interest expenses, which impacted quarterly net earnings. Monitoring the integration success and cost management will be crucial.

What was the total acquisition consideration for Nu Aire?

The aggregate acquisition consideration for Nu Aire, Inc. was $53.0 million, which included $29.669 million in cash paid and $23.0 million in subordinated promissory notes.

How does KEWAUNEE SCIENTIFIC CORP recognize revenue?

KEWAUNEE SCIENTIFIC CORP recognizes the majority of its revenue over time as the customer receives control while work is performed under a contract, with a portion recognized at a point-in-time when control is transferred per contract terms.

Risk Factors

Industry Context

The laboratory and technical furniture industry is characterized by project-based sales cycles and demand tied to capital spending in research, education, and healthcare sectors. Companies often compete on product customization, quality, and lead times. Recent trends may include increased demand for specialized containment solutions and flexible workspace designs.

Regulatory Implications

The company operates under standard business regulations. The acquisition of Nu Aire may introduce new compliance considerations depending on its specific product lines and geographic operations. No immediate significant new regulatory risks are apparent from this filing.

What Investors Should Do

  1. Monitor integration progress of Nu Aire, Inc.
  2. Analyze expense management strategies.
  3. Assess cash flow and liquidity.

Key Dates

Glossary

Net sales
The total revenue generated from the sale of goods or services, net of returns, allowances, and discounts. (Key indicator of top-line performance, significantly boosted by the Nu Aire acquisition.)
Cost of products sold
The direct costs attributable to the production of goods sold by a company. (Increased significantly, impacting gross profit margins, likely due to higher sales volume and acquisition-related costs.)
Operating expenses
Expenses incurred in the normal course of business operations, excluding cost of goods sold and interest/taxes. (Substantially increased, a major factor in the decline of net earnings for the quarter.)
Net earnings attributable to Kewaunee Scientific Corporation
The portion of the company's profit that belongs to its common stockholders after accounting for non-controlling interests. (Decreased for the quarter despite revenue growth, highlighting the impact of increased expenses.)
Comprehensive earnings
Includes net earnings plus other comprehensive income (or loss), such as foreign currency translation adjustments. (Shows the overall change in equity from non-owner sources, with foreign currency adjustments impacting the total.)
Capital expenditures
Funds used by a company to acquire, upgrade, and maintain physical assets such as property, buildings, or equipment. (Increased to $2.341 million, contributing to the decrease in cash position.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Kewaunee Scientific Corporation has demonstrated robust revenue growth of 46.7% for the quarter and 46.8% for the six months, largely driven by the Nu Aire acquisition. However, this top-line expansion has been accompanied by a significant increase in operating expenses and interest expense, leading to an 18.7% decrease in net earnings for the three-month period, although net earnings for the six-month period saw a modest 6.5% increase. The company's cash position has also declined, reflecting increased investment activities.

Filing Stats: 4,620 words · 18 min read · ~15 pages · Grade level 17.7 · Accepted 2025-12-12 09:41:25

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements Condensed Consolidated Statements of Operations (unaudited) – Three and Six Months Ended October 31, 2025 and 2024 1 Condensed Consolidated Statements of Comprehensive Earnings (unaudited) – Three and Six Months Ended October 31, 2025 and 2024 2 Condensed Consolidated Statements of Stockholders' Equity (unaudited) – Three and Six Months Ended October 31, 2025 and 2024 3 Condensed Consolidated Balance Sheets – October 31, 2025 (unaudited) and April 30, 202 5 4 Condensed Consolidated Statements of Cash Flows (unaudited) – Six Months Ended October 31, 2025 and 2024 5 Notes to Condensed Consolidated Financial Statements (unaudited) 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 23 Item 4.

Controls and Procedures

Controls and Procedures 23

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 5. Other Information 24 Item 6. Exhibits 25 SIGNATURE 26 i PART 1. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements Kewaunee Scientific Corporation Condensed Consolidated Statements of Operations (Unaudited) ($ and shares in thousands, except per share amounts) Three Months Ended October 31, Six Months Ended October 31, 2025 2024 2025 2024 Net sales $ 70,096 $ 47,764 $ 141,200 $ 96,157 Cost of products sold 50,376 33,812 100,550 69,717 Gross profit 19,720 13,952 40,650 26,440 Operating expenses 15,613 9,518 31,733 19,431 Operating profit 4,107 4,434 8,917 7,009 Other income (expense), net 407 ( 61 ) 575 266 Interest expense ( 1,061 ) ( 442 ) ( 2,119 ) ( 914 ) Profit before income taxes 3,453 3,931 7,373 6,361 Income tax expense 915 916 1,676 1,108 Net earnings 2,538 3,015 5,697 5,253 Less: Net earnings attributable to the non-controlling interest 93 7 159 52 Net earnings attributable to Kewaunee Scientific Corporation $ 2,445 $ 3,008 $ 5,538 $ 5,201 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 0.85 $ 1.05 $ 1.94 $ 1.82 Diluted $ 0.82 $ 1.01 $ 1.86 $ 1.75 Weighted average number of common shares outstanding Basic 2,866 2,872 2,859 2,861 Diluted 2,990 2,974 2,977 2,971 See accompanying notes to Condensed Consolidated Financial Statements. 1 Kewaunee Scientific Corporation Condensed Consolidated Statements of Comprehensive Earnings (Unaudited) ($ in thousands) Three Months Ended October 31, Six Months Ended October 31, 2025 2024 2025 2024 Net earnings $ 2,538 $ 3,015 $ 5,697 $ 5,253 Other comprehensive loss, net of tax: Foreign currency translation adjustments ( 164 ) ( 76 ) ( 574 ) ( 192 ) Other comprehensive loss ( 164 ) ( 76 ) ( 574 ) ( 192 ) Comprehensive earnings, net of tax 2,374 2,939 5,123 5,061 Less: Comprehensive income attributable to the non-controlling interest 93 7 159 52 Comprehensive earnings attributable to Kewaunee Scientific Corporation $ 2,281 $ 2,932 $ 4,964 $ 5,009 See accompanying notes to Condensed Consolidat

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing